Lonza Group

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lonza Group AG
Aktiengesellschaft
Traded asSIXLONN, SGX: O6Z
IndustryChemicals
biotechnology
Founded1897
HeadquartersBasel, Switzerland
Key people
Richard Ridinger (CEO), Albert Baehny (Chairman)
ProductsBiopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products
RevenueCHF 5.080 billion (2017)[1]
CHF 374 million (2010)[1]
CHF 291 million (2010)[1]
Total assetsCHF 4.778 billion (end 2010)[1]
Total equityCHF 2.387 billion (end 2010)[1]
Number of employees
14,500 (2018)
Websitewww.lonza.com

Lonza Group is a Swiss multinational, chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.

History[edit]

Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange.

The company expanded in the United States in 1969 and acquired smaller biopharmaceutical units in recent years. In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides.[2] On 15 August 2016, the group announced its intention to acquire InterHealth Nutraceuticals,[3] a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements. The acquisition of the US based company will be done at a value of up to US$300 million. In December 2016, the company announced it would acquire Capsugel for US$5.5 billion, from private equity firm KKR.[4]

Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics.[5]

Corporate structure[edit]

As of 2018, Lonza's chief executive officer (CEO) was Richard Ridinger,[6][7] while the CEO during 2010–2013 was Stefan Borgas.[8]

Business operations[edit]

As of 2018, Lonza had a twenty-four self-described major sites located in the United States, India, the Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland, Singapore, Mexico, Japan, Brazil and the United Kingdom.[6] This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites.[9] The presence in India was established in Genome Valley, where ground was broken in 2011.[8][10][11]

In 2018, Lonza opened a 300,000 square feet (28,000 m2) facility in the United States in Pearland, Texas (a suburb of Houston).[7] This is one of four sites which are focused on cell and gene therapy, the other three being in Portsmouth, New Hampshire; Geleen, Netherlands; and Singapore.[7]

As of 2016, the company employed around 10,000 people,[12]:22 across about 18 countries.[12]:89 By 2018, employment was noted as 14,500 across 100 sites.[7]

References[edit]

  1. ^ a b c d e "Annual Results 2010" (PDF). Lonza Group. Retrieved 5 February 2011.[permanent dead link]
  2. ^ Simonian, Haig (11 July 2011). "Lonza in $1.4bn acquisition of Arch Chemicals". Financial Times. Retrieved 13 November 2011.
  3. ^ "Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals" (Press release). Lonza. 15 August 2016. Retrieved 2018-04-15.[self-published source]
  4. ^ "Lonza Buys Capsugel for $5.5B Cash". Genetic Engineering & Biotechnology News. 15 December 2016. Retrieved 2018-04-15.
  5. ^ "Company History". Company Profile. Retrieved 2018-04-15.[self-published source]
  6. ^ a b "Fact Sheet". Company Profile. Lonza. Retrieved 2018-04-15.[self-published source]
  7. ^ a b c d Philippidis, Alex (10 April 2018). "Lonza Opens Cell and Gene Therapy Facility in Pearland, TX". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2018-04-15.
  8. ^ a b "Lonza to invest Rs 250 cr in Genome Valley". Business Standard. India. 25 September 2010. Retrieved 2018-04-15.
  9. ^ "Facts". Company Profile. Lonza. Archived from the original on 10 October 2016. Retrieved 2018-04-15.[self-published source]
  10. ^ "Lonza Group to set up a bio pharma unit at Genome Valley". ibis. Retrieved 2018-04-15.
  11. ^ "Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)" (Press release). Lonza. 29 May 2009.[self-published source]
  12. ^ a b "Annual Report 2016" (PDF). Investor Relations. Lonza. Retrieved 2018-04-15.[self-published source]

External links[edit]